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Abstract 
 
Background:  Dysregulated production of TNF has been implicated in the 
pathogenesis and severity of inflammatory rheumatic diseases, many of which show 
age-related increased incidence.  Ageing is also associated with changes in the 
immune system including higher systemic levels of pro-inflammatory cytokines.  
Methylation of DNA is an important regulator of gene expression and changes with 
age.   
 
Objective:  In this study we investigated whether the DNA methylation status of the 
TNF promoter changed with age in peripheral blood leukocytes and macrophages.    
 
Methods and results:  Using pyrosequencing assays we detected age-related 
demethylation of CpG motifs (-304, -245 and -239) in the TNF promoter in human 
peripheral blood cells from 312 healthy controls (0.8% per decade, confidence 
interval (CI)=0.44%-1.13%, p=1x10-5) and primary monocyte-derived macrophages 
(MDM) from a separate population of 78 healthy controls (1.4% per decade, 
CI=0.79%-2.13%, p=7x10-5).  Methylation a TNF promoter fragment (-345 to +154) 
resulted in 78% reduction of reporter gene activity compared with the unmethylated 
promoter construct.   
 
Conclusions:  These data suggest a potential role of accrued changes in DNA 
methylation in the development of age-related inflammatory diseases, such as 
rheumatoid arthritis and polymyalgia rheumatica, in which TNF is a pivotal mediator. 
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1.  Introduction 
 
The cytokine TNF is a potent immunomodulating and pro-inflammatory mediator 
with a wide range of activities [1].  The main cellular source of TNF is the 
macrophage although significant quantities are produced by other sources such as T 
and B cells.  Systemic levels of TNF are correlated with outcome from severe 
infections including malaria [2] and meningococcal disease [3], whilst the therapeutic 
efficacy of TNF inhibitors for the treatment of polymyalgia rheumatica (PMR) [4] and 
rheumatoid arthritis (RA) [5] confirms its central role in these conditions.   
 
The production of TNF is primarily controlled at the transcriptional and post-
transcriptional levels [6].  In response to lipopolysaccharide (LPS) stimulation of 
macrophages, TNF transcription increases 3-fold, TNF mRNA levels increase 50 to 
100-fold and protein production increases approximately 10,000-fold [1].  Sequences 
within the 1,100bp stretch of DNA between the 3’ end of the adjacent lymphotoxin-α 
gene and the first exon of the TNF gene are central in the control of transcription [7, 
8].  Production of TNF shows stable inter-individual variation [9] and alleles of the 
TNF promoter have been correlated with levels of gene expression [10, 11].  
 
Many aspects of the both the adaptive and innate immune systems change with 
increasing age leading to a state termed ‘inflammageing’ [12].  In the adaptive system 
the ability to generate high affinity antibodies after immunization is reduced perhaps 
as result of reduced levels of CD8+ CD28- cells [13], in addition to the ratio of naïve 
to memory T cells alters [14].  Age-related changes in the innate immune system 
include higher systemic levels of pro-inflammatory cytokines and most studies have 
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shown higher LPS-induced production of pro-inflammatory cytokines by 
macrophages from older individuals [15, 16].  The expression of Toll-like receptor 
TLR 1 by macrophages from healthy older individuals (>65 yrs old) is 39% less than 
levels from your subjects (21-30 yrs old) with resultant decreased production of pro-
inflammatory cytokines following TLR1/2 activation [17].  
 
Although recent studies have challenged the belief that global DNA methylation 
decreases with age [18, 19], recent evidence suggests that immune genes may be 
particularly prone to age-related change in DNA methylation [18].  The expression of 
killer Ig-like receptors on T cells is known to increase with age and KIR2DL4 
promoter methylation is lower in T cells isolated from 70-80 year old donors 
compared with those from 20-40 year old individuals [20].   
 
We hypothesized that age-related changes in the methylation signature of the TNF 
promoter could contribute to the higher expression of this cytokine in older 
individuals.   To explore this possibility we developed pyrosequencing assays to 
determine the methylation of CpG motifs around the transcriptional start site (-349 to 
-78).   We report age-related reduced methylation in both peripheral blood leukocytes 
(PBL) and monocyte-derived macrophages (MDM) from separate healthy control 
populations.  The role of DNA methylation in regulating TNF gene expression was 
determined a reporter gene assay.  Our data suggests that lower DNA methylation in 
the TNF promoter may contribute to both the age-related increased production of this 
cytokine and the higher incidence of inflammatory diseases.  
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2.  Materials and Methods 
 
2.1  Blood sample collection.  
Peripheral blood samples were collected from 312 healthy controls. as part of a large 
study of rheumatoid arthritis, all subjects were 18 years of age or older with no history 
of inflammatory joint disease [21].  The MDM were collected from 78 healthy 
students and staff in the Sheffield Medical School and were isolated from 100 ml of 
peripheral blood by density gradient centrifugation using standard techniques as 
previously described [22].  Cells were cultured for 7 days in flat-bottomed 24-well 
plates (1 x 106 cells/well), in 1ml RPMI 1640 medium/well (Invitrogen Ltd, Paisley, 
UK) supplemented with 2mM L-glutamine and 10% foetal calf serum (FCS), at 37ºC 
in 95% air, 5% CO2 prior to DNA extraction.  Approval for both cellular collections 
was obtained from the South Sheffield Research Ethics Committee and informed 
consent was obtained from all donors.  DNA was extracted using sodium perchlorate 
and chloroform. 
 
2.2  Bisulphite pyrosequencing.  
Prior to sequencing DNA was incubated with sodium bisulphite using the EpiTect® 
kit (Qiagen, Crawley, West Sussex) according to the manufacturers protocol. Forward 
and biotin labelled reverse primers were designed against bisulphite-modified 
sequences and sequencing primers were designed using the Pyrosequencing Assay 
Design (Biotage, Uppsala, Sweden).  Amplification reactions were performed in 1 x 
PCR reaction buffer and 200µM of each dNTP, 0.2µM forward and reverse primers 
(Table 1) and 1U Qiagen HotStarTaq.  An initial incubation of 95ºC for 15 minutes 
was followed by 50 cycles of 1 minute at 94ºC, 1 minute at 55ºC and 1 minute at 72ºC 
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with a final elongation step of 72ºC for 10 minutes. The PCR product was bound to 
streptavidin-sepharose beads (2µl) (GE Healthcare, Uppsala, Sweden), washed 
sequentially in 70% ethanol, 0.2M sodium hydroxide and wash buffer (10mM Tris-
Acetate, pH 7.6) and the single stranded DNA was eluted into the sequencing reaction 
containing 0.3µM sequencing primer (Table 1) in 20mM Tris-Acetate, 2mM Mg-
Acetate pH 7.6. The sequencing reaction was incubated at 80ºC for 5 minutes 
followed by pyrosequencing on the PyroMark MD (Biotage). 
 
2.3  Reporter gene assays 
A TNF promoter fragment (-345 to +154) was amplified using high fidelity DNA 
polymerase (Phusion, New England Biolabs, Ipswich, MA) with forward and reverse 
primers containing BglII and HindIII restriction sites respectively (Table 1).  The 
fragment was cloned into a pCR2.1 vector using TA overhangs and verified by 
sequencing. The promoter fragment was excised, using BglII and HindIII, and cloned 
into the multiple cloning site of the CpG-less vector pCpG-basic kindly provided by 
Michael Rehli and Maja Klug. The construct was methylated by incubation for 2 
hours at 37ºC in the presence or absence  of 2.5U Sss1 (New England Biolabs) with 
160µM S-adenosylmethionine.   Methylation was assessed by pyrosequencing and 
was >90%.  Methylated and unmethylated constructs were purified using Qiaquick 
columns (Qiagen) and were used to transfect HeLa cells using Superfect transfection 
reagent (Qiagen).  As a control for transfection efficiency the promoter fragment of 
the murine EF1 alpha gene was amplified by PCR and subcloned into pGL4-Renilla 
Luciferase (Promega) reporter and was used as an internal control in the luciferase 
assays (a kind gift of Dr David Wylie), 24 hours post-transfection cells were 
stimulated for 6 hours with or without 5ng/ml IL-1β.  Luciferase and Renilla activities 
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were measured using the Dual-Luciferase Reporter System (Promega) according to 
the manufacturer’s protocol. 
 
2.4  Statistical Analyses 
Because of the clear differences in the methylation levels at the 5’ and proximal CpGs 
we analysed the two regions separately. Within each region we treated the CpGs as 
repeated measures of methylation in the same individual.  All analyses were 
performed using a mixed effects model in which we included the intra-individual 
correlations between the methylation levels at the CpG sites.  When considering the 
change in methylation with age, this variable was entered into the model as a 
continuous variable and gender as a two-level factor variable.  Treating the two 
regions separately meant that the model assumptions of normally distributed error 
terms were met.  There were missing values in the data but only individuals with all 
CpGs missing in a region were excluded.  Generalized likelihood ratio tests are 
preferentially used in fixed effects models for comparing random effects structures for 
a given fixed effects structure, however they can be anti-conservative in assessing 
fixed effects within a mixed effects model; so we use the more reliable Wald tests.  
Confidence intervals were calculated in the same way using the estimated standard 
errors and t-distribution assumptions.  
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3.  Results 
 
3.1  Age-related loss of DNA methylation of CpG motifs in the TNF promoter 
region. 
The pyrosequencing assays determined the methlyation of the TNF promoter (-349 to 
-78) containing 7 CpG motifs (Figure 1).  The initial study was performed on PBL 
from 312 healthy controls (age range 20-84 years).  Relative methylation differed 
within the promoter fragment; the three 5’ CpG motifs (-304, -245 and -239) were 
highly methylated (>80%) whereas the proximal motifs (-170, -164, -162 and -147) 
were predominantly unmethylated (<20%).  Using the mixed effects statistical model 
we tested whether the methylation pattern changed with age; it deceased at the three 
5’ CpGs by 0.8% per decade (CI=0.44%-1.13%, p=1x10-5) with a smaller but 
statistically significant fall in the proximal motifs (p=0.03) (Fig. 2A & B 
respectively).  
 
We then performed a similar study on MDM obtained from a separate population of 
78 healthy controls.   Methylation of the 5’ CpGs (>80%) was high compared with 
that of the 3’ motifs (<20%).   In this less heterogenous cell population methylation of 
the 5’ motifs decreased by 1.4% per decade (CI=0.79%-2.13%, p=7x10-5) (Fig. 2C), 
however methylation of the 3’ motifs did not change with age (Fig. 2D). 
 
Genomic DNA methylation was assessed using a LINE-1 methylation assay and did 
not change with age in either PBL or MDM (Fig. 2E & F).   
 
3.2  Gender-related differences in DNA methylation 
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Global methylation was significantly lower in MDM from female donors compared 
with males, although the absolute difference was relatively modest (81.1% v 82.1% 
respectively, p=0.004), and was not different in PBLs (p=0.08) (Table 2).   
 
3.3  Effects of methylation of a TNF reporter gene construct 
To determine the transcriptional effect of TNF promoter methylation, the HeLa cell 
line was transfected with methylated or unmethylated TNFprom-PCpGL vectors, and 
following incubation with 5 ng/ml interleukin-1β, reporter activity was determined.  
Methylation resulted in a 78% reduction in reporter gene expression (CI=33-128%, 
p<0.001) compared with the unmethylated promoter (Fig. 3B).  Although the assay 
examined the effects of methylation of all of the CpGs motifs in the TNF promoter 
fragment rather than the three 5’ motifs this data suggests an important role of DNA 
methylation in regulating TNF transcription. 
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4.  Discussion 
 
In humans, ageing is associated with significant changes in the innate immune system 
including impairment of neutrophil and macrophage phagocytic activity, increased 
production of pro-inflammatory cytokines and reduced antibacterial defence [23].  
Our data revealing age-related reduction of DNA methylation of the TNF promoter 
suggest that age-related loss of the epigenetic signature of this cytokine may 
contribute to inflammaging and contributing to the pathogenesis of late onset 
rheumatic diseases such as PMR and RA in which this cytokine has been shown to a 
pivotal mediator of chronic inflammation [24, 25]. 
 
Genome wide association studies have resulted in significant advances in our 
understanding of the genetic basis of common multifactorial diseases, however the 
heritability of many of these conditions is relatively modest implying significant non-
genetic or environmental contributions.  Autoimmune diseases, such as rheumatoid 
arthritis and type 1 diabetes, affect approximately 4% of the population of Western 
Europe and the United States and have features suggestive of an epigenetic effect 
including discordance in monozygotic twins, relatively late onset (commonly in the 
4th or 5th decade), female predominance and parent-of-origin effects [26].  In many of 
these conditions TNF acts as a pivotal mediator of inflammation and tissue damage; 
our data suggests that age-related DNA TNF promoter demethylation could contribute 
to the late peak in incidence of these conditions [27].  The relationship between 
gender and methylation status is controversial; lower genomic levels have been 
reported in peripheral blood white cells of healthy females [28], however another 
study examined mean methylation in a range of organs and primary cell types did not 
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detect significant gender-related differences [19].   Levels of DNA methylation are 
lower in peripheral blood T cells from patients with either rheumatoid arthritis or 
systemic lupus erythematosus compared with healthy controls [29], both of which 
occur more frequently in females, although whether this is a primary abnormality or is 
secondary to the disease or its treatment is not known.  
 
Early studies of genomic DNA methylation reported it to decrease with age [29, 30], 
however recent evidence indicates that this relationship is more complex.  In 
monozygotic twins the patterns of global and gene specific DNA methylation is very 
similar in younger twins however older twins (age>50 years) have significant 
differences especially if they that had spent less time together in earlier life [31].  A 
recent study reported positive correlations between CpG island methylation and 
ageing, however methylation of CpG motifs not in CpG islands was negatively 
correlated with ageing [32]. The complexity of age-related DNA methylation 
alterations was further highlighted in a family-based study that reported no overall 
change during an 11 years interval however there was a significant heritable 
component of this trait [18].   
 
The potential mechanism of age-related demethylation of a single locus is not clear; 
the cellular activity of DNA methyltranserase 1 decreases with age but this is likely to  
lead to a global loss in methylation which we did not observe [33].  Another potential 
mechanism is related to the effects of chronic age-related low grade inflammation 
leading to the production of reactive oxidative molecules with resultant conversion of 
5-methylcytosine to 5-hydroxymethylcytosine [34].  This modification interfers with 
the activities of DNA methyltransferase 1 with failure to methylate target cytosines 
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[34], however once again this mechanism would also be expected to result in a 
genomic rather than a gene specific change in methylation.  The conversion of 5-
methylcytosine to 5-hydroxymethylcytosine is regulated by members of the TET 
protein family [35], however little is known of the effects of ageing on TET. 
 
The role of DNA methylation in cancer has been convincingly demonstrated, however 
its role in determining risk or outcome of inflammatory diseases is much less clear.  
This is partly due to the technical challenges in performing large-scale assays of DNA 
methylation that are sufficiently sensitive to detect relatively modest differences such 
as those found in our study.  Our findings suggest that assessment of the methlyation 
status of TNF could have utility as a biomarker of susceptibility to, or severity of, the 
many inflammatory and infectious diseases in which TNF is a pivotal mediator.  The 
clinical use of anti-TNF agents has revolutionized the treatment of RA and Crohn’s 
disease and TNF promoter variants have been correlated with response [36].   As 
macrophages are the primary cellular source of TNF our data suggest that the 
epigenetic signature of the TNF promoter could be a further marker of response to 
these agents.   A further potential clinical impact is therapeutic modulation of the 
epigenetic signature of patients with chronic inflammatory diseases, aimed at 
returning dysregulated gene expression to a homeostatic setting.  The change in the 
epigenetic signature with age is likely to be significantly determined by 
environmental exposures, including diet, tobacco smoke, alcohol and previous 
illnesses and therapies [31].  
 
4.1  Study limitations 
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There are several limitations to our study.  The change in methylation of the TNF 
promoter in PBL could be secondary to an age-related change in the cellular 
composition of PBL however MDM represent a more homogenous cellular type. 
Furthermore the biological consequences of relatively modest changes in TNF 
promoter methylation on TNF expression is not clear.  Although the reporter gene 
experiments underlined the potential importance of promoter methylation on 
expression the assay determined the effects of methylation of the whole promoter 
fragment rather than individual or clusters of CpGs. 
 
4.2  Conclusions 
In summary we report age-related loss of methylation of TNF CpG motifs in both 
peripheral blood leucocytes and macrophages and demonstrate a significant effect of 
DNA methylation on gene expression.  Although the changes were relatively modest 
it could be that similar changes in the genes encoding other key regulators of 
inflammation could have synergistic effects leading to larger biological consequences 
leading to the development of age-related inflammatory rheumatic diseases such as 
RA and PMR.   The recent advances in ultra high throughput DNA sequencing 
technology will facilitate studies to determine the role of epigenetics in the 
development of inflammageing. 
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Table 1.  Oligonucleotide sequences for pyrosequencing, TNF fragment 
amplification for cloning and TNF mRNA quantitative PCR. 
 
Gene TNF     
 
 
 
CpG -304    -245, -239    -170, -164,  -162, -147  LINE-1 
Plasmid construct Forward Reverse  
Pyrosequencing Forward Reverse Sequencing  Forward Reverse Sequencing  Forward Reverse Sequencing  Forward Reverse Sequencing  Forward Reverse Sequencing 
Primer sequence 5’ AGATCTCCAAAAGAAATGGAGGCAAT 3’ 5’ AAGCTTGAAGCCGTGGGTCAGTATGT 3’   5’ TTGGTTTTTAAAAGAAATGGAGGT 3’ 5’ Biotin ATAATAAACCCTACACCTTCTATCT 3’ 5’ GGTTTTGAGGGGTATG 3’  5’ TGGGGAAGGGGTTTAGTTTTTAG 3’ 5’ Biotin TCAAAAATACCCCTCACACTC 3’ 5’ TAGTGGTTTAGAAGATTTTT 3’  5’ AATTTTTTTGGTGGAGAAATTTATG 3’ 5’ Biotin CCTACACACAAATCAATCAATAACC 3’ 5’ GGGTTTTGTATTTTTTGTTT 3’  5’ TTTTTGAGTTAGGTGTGGGATATA 3’ 5’ Biotin AAAAATCAAAAAATTCCCTTTC 3’ 5’ AGTTAGGTGTGGGATATAGT 3’  5’ TTTTTGAGTTAGGTGTGGGATATA 3’ 5’ Biotin AAAAATCAAAAAATTCCCTTTC 3’ 5’ AGTTAGGTGTGGGATATAGT 3’  
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Table 2.  The methylation status of the TNF promoter 5’ CpG motifs (-304, -245 
and -239) and global methylation in PBCs and MDMs derived from males and 
females. 
 
Cells Gene  Mean 
Methylation 
P 
Macrophages 
 
TNF 
 
 
LINE1 
Males 
Females 
 
Males 
Females 
 
84.1 
83.2 
 
82.1 
81.1 
 
0.343 
 
 
0.004** 
PBC TNF 
 
 
LINE1 
Males 
Females 
 
Males 
Females 
 
80.2 
80.3 
 
82.4 
81.6 
0.788 
 
 
0.08 
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Legends to figures. 
 
Figure 1.  Structure of the TNF promoter including transcription factor 
consensus sequences, CpG motifs and single nucleotide polymorphisms. 
 
Figure 2.  Age-related change in DNA methylation of CpG motifs in the TNF 
promoter region.  Pyrosequencing assays were used to quantitate methylation of 
CpG motifs in the distal (-304, -245 and -239) and proximal regions (-170, -164, -162, 
-147 and -120) of the TNF promoter in PBLs (A & B respectively) and MDMs (C & 
D respectively).  The percentage change in DNA methylation per decade is given for 
statistically significant results.  Global DNA methylation in PBLs (E) and MDMs (F) 
was determined using a LINE-1 methylation assay.  
 
Figure 3.  Effects of TNF promoter methylation on reporter gene expression.   
Methylation of the TNF promoter fragment downregulates reporter gene expression.  
The TNF promoter fragment was cloned upstream of the luciferase reporter gene in 
the PCpGL vector and unmethylated (hashed bar) or Sss1 methylated (solid bar) 
vectors these were used to transfected HeLa cells.  Cells were incubated with or 
without IL-1β and luciferase activity was measured. Bars represent mean with error 
bars showing SEM.  Analysis was performed using ANOVA (n = 9 from 3 
independent experiments). 
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